These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 27327958)
1. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958 [TBL] [Abstract][Full Text] [Related]
2. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer]. Chen ZY; Dong Q; Liu LR; Wei Q Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207 [TBL] [Abstract][Full Text] [Related]
3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Galletti G; Leach BI; Lam L; Tagawa ST Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407 [TBL] [Abstract][Full Text] [Related]
6. Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC). Boegemann M; Schrader AJ; Krabbe LM; Herrmann E Curr Cancer Drug Targets; 2015; 15(3):243-55. PubMed ID: 25654638 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Crona DJ; Milowsky MI; Whang YE Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358 [TBL] [Abstract][Full Text] [Related]
9. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270 [TBL] [Abstract][Full Text] [Related]
10. [New generation of androgen receptor antagonist in castration resistant prostate cancer]. Uemura H Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352 [TBL] [Abstract][Full Text] [Related]
11. Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance. Jian J; Wang X; Zhang J; Zhou C; Hou X; Huang Y; Hou J; Lin Y; Wei X Front Endocrinol (Lausanne); 2024; 15():1360430. PubMed ID: 38887275 [TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683 [TBL] [Abstract][Full Text] [Related]
13. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further. Fujimoto N J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726 [TBL] [Abstract][Full Text] [Related]
14. [Methods for androgen receptor splice variant-7 detection: Advances in studies]. Li K; Fan GR; Chen CH; Wang ZP Zhonghua Nan Ke Xue; 2019 Nov; 25(11):1031-1035. PubMed ID: 32233239 [TBL] [Abstract][Full Text] [Related]
15. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Kim W; Ryan CJ Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176 [TBL] [Abstract][Full Text] [Related]
16. Molecular landscape of prostate cancer: implications for current clinical trials. Khemlina G; Ikeda S; Kurzrock R Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103 [TBL] [Abstract][Full Text] [Related]
17. Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Lorente D; Mateo J; Zafeiriou Z; Smith AD; Sandhu S; Ferraldeschi R; de Bono JS Nat Rev Urol; 2015 Jan; 12(1):37-47. PubMed ID: 25563847 [TBL] [Abstract][Full Text] [Related]
18. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747 [TBL] [Abstract][Full Text] [Related]
19. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Lokhandwala PM; Riel SL; Haley L; Lu C; Chen Y; Silberstein J; Zhu Y; Zheng G; Lin MT; Gocke CD; Partin AW; Antonarakis ES; Luo J; Eshleman JR J Mol Diagn; 2017 Jan; 19(1):115-125. PubMed ID: 27916435 [TBL] [Abstract][Full Text] [Related]
20. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Bastos DA; Dzik C; Rathkopf D; Scher HI Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]